Silexion Therapeutics receives Nasdaq panel approval for continued listing

Silexion Therapeutics (SLXN) has secured continued listing on Nasdaq, transferring from the Global Market to the Capital Market following a favorable hearing panel decision. This reprieve is conditional on the company restoring $2.5 million in shareholders' equity by September 19, 2025, and addressing a potential minimum bid price deficiency through a proposed 1-for-15 reverse stock split, pending shareholder approval. While avoiding immediate delisting, SLXN faces significant compliance hurdles and remains under Nasdaq's jurisdiction until November 18, 2025, signaling ongoing financial instability and operational challenges.

Analysis

Silexion Therapeutics (SLXN) has secured a temporary reprieve from delisting, with a Nasdaq hearings panel approving its continued listing conditional upon a transfer from the Nasdaq Global Market to the Nasdaq Capital Market. This decision, while avoiding an immediate delisting, subjects the company to rigorous compliance hurdles. Silexion must demonstrate it has restored at least $2.5 million in shareholders' equity by September 19, 2025, a clear indicator of its current balance sheet weakness. Furthermore, the company anticipates a new deficiency related to the minimum bid price rule, which it plans to address via a proposed 1-for-15 reverse stock split. This action is contingent on shareholder approval on July 14, 2025, introducing significant execution risk. The company itself acknowledges there is no assurance it will meet all requirements, and Nasdaq's continued jurisdiction until November 18, 2025, underscores the sustained and precarious nature of its financial and operational standing.

Key Decisions for Investors

• Investors should view Silexion's continued listing as highly conditional and speculative, with key compliance deadlines in September and November 2025 acting as major catalysts for volatility.
• The upcoming shareholder vote on July 14, 2025, regarding the 1-for-15 reverse stock split is a critical event; failure to secure approval would likely precipitate a delisting notice for violating the minimum bid price requirement.
• Given the requirement to restore $2.5 million in shareholders' equity, investors should scrutinize upcoming SEC filings for balance sheet improvements, as this is a non-negotiable condition for maintaining its Nasdaq listing.
• The move to the Nasdaq Capital Market is a formal downgrade, and coupled with the planned reverse split, signals significant underlying financial distress that warrants extreme caution for both current and prospective shareholders.